Autologous T cell(Shenzhen Yishi Kangning)

自体T细胞（深圳益世康宁）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous T cell(Shenzhen Yishi Kangning)
Drug Alias Name非小细胞肺腺癌复合抗原致敏的树突状细胞所激活的自体T细胞
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesImmuclin Biomed Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmuclin Biomed Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A